CL2012000882A1 - Compuestos derivados de piperidinilo, moduladores de la actividad del receptor de quimiocina; composicion farmaceutica que los comprende; y su uso para el tratamiento de artritis reumatoide, osteoartritis, aneurisma, fiebre, psoriasis, enfermedad inflamatoria del intestino, aterosclerosis, cancer, entre otras. - Google Patents
Compuestos derivados de piperidinilo, moduladores de la actividad del receptor de quimiocina; composicion farmaceutica que los comprende; y su uso para el tratamiento de artritis reumatoide, osteoartritis, aneurisma, fiebre, psoriasis, enfermedad inflamatoria del intestino, aterosclerosis, cancer, entre otras.Info
- Publication number
- CL2012000882A1 CL2012000882A1 CL2012000882A CL2012000882A CL2012000882A1 CL 2012000882 A1 CL2012000882 A1 CL 2012000882A1 CL 2012000882 A CL2012000882 A CL 2012000882A CL 2012000882 A CL2012000882 A CL 2012000882A CL 2012000882 A1 CL2012000882 A1 CL 2012000882A1
- Authority
- CL
- Chile
- Prior art keywords
- aneurysm
- osteoarthritis
- psoriasis
- atherosclerosis
- modulators
- Prior art date
Links
- 206010002329 Aneurysm Diseases 0.000 title abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 title abstract 2
- 102000009410 Chemokine receptor Human genes 0.000 title abstract 2
- 108050000299 Chemokine receptor Proteins 0.000 title abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000004681 Psoriasis Diseases 0.000 title abstract 2
- 206010037660 Pyrexia Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 201000008482 osteoarthritis Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 125000003386 piperidinyl group Chemical group 0.000 title 1
- 206010039073 rheumatoid arthritis Diseases 0.000 title 1
- -1 piperidinyl derivative compound Chemical class 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24927009P | 2009-10-07 | 2009-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012000882A1 true CL2012000882A1 (es) | 2012-09-07 |
Family
ID=43334406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012000882A CL2012000882A1 (es) | 2009-10-07 | 2012-04-05 | Compuestos derivados de piperidinilo, moduladores de la actividad del receptor de quimiocina; composicion farmaceutica que los comprende; y su uso para el tratamiento de artritis reumatoide, osteoartritis, aneurisma, fiebre, psoriasis, enfermedad inflamatoria del intestino, aterosclerosis, cancer, entre otras. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8410139B2 (enExample) |
| EP (1) | EP2486013B1 (enExample) |
| JP (1) | JP5788397B2 (enExample) |
| KR (1) | KR20120083900A (enExample) |
| CN (1) | CN102648179B (enExample) |
| AR (1) | AR078543A1 (enExample) |
| AU (1) | AU2010303441A1 (enExample) |
| BR (1) | BR112012007755A2 (enExample) |
| CA (1) | CA2777032A1 (enExample) |
| CL (1) | CL2012000882A1 (enExample) |
| CO (1) | CO6440510A2 (enExample) |
| EA (1) | EA022150B1 (enExample) |
| IL (1) | IL219122A (enExample) |
| MX (1) | MX2012003656A (enExample) |
| NZ (1) | NZ599261A (enExample) |
| PE (1) | PE20121109A1 (enExample) |
| TW (1) | TW201118070A (enExample) |
| WO (1) | WO2011044309A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3129016T (pt) | 2014-04-08 | 2018-10-01 | Neurovive Pharmaceutical Ab | Compostos novos |
| AR106018A1 (es) * | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| EP3589287B1 (en) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
| CN110776481B (zh) * | 2018-07-24 | 2023-06-16 | 四川大学华西医院 | 一类双阳离子化合物及其制备方法和用途 |
| CN108727248B (zh) | 2018-07-25 | 2021-05-25 | 四川大学华西医院 | 一类双季铵化合物及其制备方法和用途 |
| EP3898617A4 (en) | 2018-12-17 | 2022-08-17 | Achillion Pharmaceuticals, Inc. | TARGETED DOSAGE FOR THE TREATMENT OF COMPLEMENT INDUCED DISORDERS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU770042B2 (en) * | 1998-12-18 | 2004-02-12 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| JP2006520783A (ja) * | 2003-03-18 | 2006-09-14 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体活性のアミノシクロブチルアミド調節物質 |
| US7601844B2 (en) * | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| AU2007275931B2 (en) * | 2006-07-19 | 2011-06-16 | Astrazeneca Ab | Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity |
| WO2009015164A2 (en) | 2007-07-24 | 2009-01-29 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| EP2173714B9 (en) | 2007-07-24 | 2013-04-10 | Bristol-Myers Squibb Company | Piperidine derivatives as modulators of chemokine receptor activity |
| TWI433838B (zh) * | 2008-06-25 | 2014-04-11 | 必治妥美雅史谷比公司 | 作為趨化因子受體活性調節劑之六氫吡啶衍生物 |
-
2010
- 2010-10-04 US US12/896,955 patent/US8410139B2/en active Active
- 2010-10-06 AR ARP100103636A patent/AR078543A1/es unknown
- 2010-10-06 TW TW099134093A patent/TW201118070A/zh unknown
- 2010-10-07 KR KR1020127011586A patent/KR20120083900A/ko not_active Withdrawn
- 2010-10-07 CA CA2777032A patent/CA2777032A1/en not_active Abandoned
- 2010-10-07 WO PCT/US2010/051731 patent/WO2011044309A1/en not_active Ceased
- 2010-10-07 NZ NZ599261A patent/NZ599261A/xx not_active IP Right Cessation
- 2010-10-07 MX MX2012003656A patent/MX2012003656A/es active IP Right Grant
- 2010-10-07 JP JP2012533303A patent/JP5788397B2/ja not_active Expired - Fee Related
- 2010-10-07 EP EP10766190.2A patent/EP2486013B1/en not_active Not-in-force
- 2010-10-07 AU AU2010303441A patent/AU2010303441A1/en not_active Abandoned
- 2010-10-07 BR BR112012007755A patent/BR112012007755A2/pt not_active IP Right Cessation
- 2010-10-07 EA EA201270468A patent/EA022150B1/ru not_active IP Right Cessation
- 2010-10-07 CN CN201080055421.4A patent/CN102648179B/zh not_active Expired - Fee Related
- 2010-10-07 PE PE2012000437A patent/PE20121109A1/es not_active Application Discontinuation
-
2012
- 2012-03-29 CO CO12053565A patent/CO6440510A2/es active IP Right Grant
- 2012-04-05 IL IL219122A patent/IL219122A/en not_active IP Right Cessation
- 2012-04-05 CL CL2012000882A patent/CL2012000882A1/es unknown
-
2013
- 2013-03-05 US US13/785,039 patent/US20130178444A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012003656A (es) | 2012-04-30 |
| EA022150B1 (ru) | 2015-11-30 |
| EP2486013B1 (en) | 2015-07-08 |
| CN102648179B (zh) | 2015-06-17 |
| NZ599261A (en) | 2013-10-25 |
| EA201270468A1 (ru) | 2012-11-30 |
| AU2010303441A1 (en) | 2012-05-03 |
| CA2777032A1 (en) | 2011-04-14 |
| WO2011044309A1 (en) | 2011-04-14 |
| US20130178444A1 (en) | 2013-07-11 |
| CN102648179A (zh) | 2012-08-22 |
| US20110082113A1 (en) | 2011-04-07 |
| TW201118070A (en) | 2011-06-01 |
| PE20121109A1 (es) | 2012-08-20 |
| US8410139B2 (en) | 2013-04-02 |
| AR078543A1 (es) | 2011-11-16 |
| BR112012007755A2 (pt) | 2015-09-15 |
| KR20120083900A (ko) | 2012-07-26 |
| JP2013507377A (ja) | 2013-03-04 |
| CO6440510A2 (es) | 2012-05-15 |
| EP2486013A1 (en) | 2012-08-15 |
| IL219122A (en) | 2015-04-30 |
| JP5788397B2 (ja) | 2015-09-30 |
| IL219122A0 (en) | 2012-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012000882A1 (es) | Compuestos derivados de piperidinilo, moduladores de la actividad del receptor de quimiocina; composicion farmaceutica que los comprende; y su uso para el tratamiento de artritis reumatoide, osteoartritis, aneurisma, fiebre, psoriasis, enfermedad inflamatoria del intestino, aterosclerosis, cancer, entre otras. | |
| CL2010001637A1 (es) | Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras. | |
| CR11582A (es) | Compuestos heterociclicos y sus usos | |
| CL2011002745A1 (es) | Compuestos derivados de acidos grasos poliinsaturados; metodo de preparacion; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de trastornos cardiovasculares, metabolicos e inflamatorios, tales como, artritis reumatoide, aterosclerosis, diabetes, dislipidemia, entre otras. | |
| CL2017003258A1 (es) | Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| ECSP11010932A (es) | Compuestos de azaindazol como antagonistas del receptor de ccr1 | |
| CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
| ECSP11011390A (es) | Compuestos espiro-amidas sustituidas | |
| SV2010003777A (es) | Compuestos organicos | |
| CR20110028A (es) | Derivados de pirimidina como inhibidores de cinasa | |
| CL2014000642A1 (es) | Compuestos derivados de indazol-3-carboxamidas, como inhibidores de la ruta de señalizacion de wnt/b-catenina; composicion farmaceutica que los comprende; y su uso para el tratamiento de cancer, artritis reumatoide, infecciones micoticas y viricas, enfermedad de parkinson, un trastorno fibrotico, entre otras enfermedades. | |
| CL2012001627A1 (es) | Compuestos derivados de 1,3-tiazol-fenilaminopirimidinas, inhibidores de syk; composición farmacéutica; y su uso para el tratamiento de la artritis reumatoide y cancer. | |
| CL2011002942A1 (es) | Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2013000675A1 (es) | Compuestos derivados de pirazolamida sustituidas, con actividad sobre pge2/ep4; composicion farmaceutica que los comprende; y su uso para el tratamiento de la esclerosis multiple y la artritis reumtoide. | |
| CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
| ECSP11011347A (es) | Nicotinamida sustituida como moduladores KCNQ2/3 | |
| UY31048A1 (es) | Nuevos compuestos de pirimidina y usos de los mismos | |
| CR20110309A (es) | Compuestos orgánicos | |
| ECSP11011184A (es) | Compuestos orgánicos | |
| CL2011000087A1 (es) | Compuestos derivados de heteroarilo sustituido, inhibidores de los receptores dgat1; composicion farmaceutica; y su uso para tratar la diabetes tipo ll y obesidad. | |
| ECSP11011348A (es) | 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3 | |
| HN2008001464A (es) | Formulaciones para administrcion parenteral de compuestos y sus usos | |
| AR069474A1 (es) | Material anticorrosivo | |
| CL2008003690A1 (es) | Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos. | |
| ECSP13012519A (es) | Compuestos sustituidos de benzamida |